Phase 2 N=90 Zalutumumab in Non-curable Patients With SCCHN
Head and Neck Cancer · Squamous Cell Cancer
Primary: Overall Survival (OS) — 5.3 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=471 Family-supported Smoking Cessation for Chronically Ill Veterans
Chronic Disease · Neoplasm · Cardiovascular Disease
Primary: The Impact of a Family-supported Intervention on Rates of Abstinence From Cigarettes Compared to a Standard Intervention — 19.8; 22.0 percentage of participants that quit
Phase 2 N=197 Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
Transfusional Iron Overload · Transfusional Hemosiderosis
Primary: Core Study: Change From Baseline in Myocardial T2* (Magnetic Resonance T2-star (T2*) Technique for the Measurement of Tissue Iron) After 12 Months Treatment — 1.12; 1.07…
N/A N=208 Mindfulness to Improve Elders' Immune and Health Status
Stress, Psychologic
Primary: IgG Anti-KLH Antibody Response Post-treatment — 0.172; 0.104 OD 405 nm — p=.007
N/A N=108 Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Postmortem
Cognitive Impairment
Primary: The Number of Abnormal Blinded Visual PET Image Interpretations. — 73; 68; 67; 67 Number of Blinded Image Interpretations
Phase 4 N=578 Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Pre-dose FEV1 — 1.050; 1.006 Ratio — p=0.0004
N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
Phase 2 N=14 Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · 21-Hydroxylase Deficiency · Adrenogenital Syndrome
Primary: Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose)…
Phase 4 N=682 A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis
Rhinitis, Allergic, Perennial and Seasonal
Primary: Mean Change From Baseline (CFB) in the Individual AM Reflective Total Nasal Symptom Scores (rTNSS) Over the Entire Treatment Period — -2.2; -1.9; -1.5; -0.9 Scores on a…
N/A N=36 Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
AML
Primary: Association Between the Magnitude of mTOR Target Inhibition Post-treatment in Leukemic Blasts and Clinical Response in Patients With High Risk AML Treated With Sirolimus…
Phase 2 N=111 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease
Behcet Syndrome
Primary: Number of Oral Ulcers at Day 85 — 2.0; 0.4 ulcers/participants — p=<0.0001
Phase 4 N=295 Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus
Kidney Transplant
Primary: Percentage of Participants Who Had Initiated Losartan Therapy at 52 Weeks Following Conversion to SRL — 6.2; 23.2 percentage of participants — p=0.0002
Phase 2 N=186 Phase IIb Study of STA-2 in Patients With Chronic Stable Angina
Chronic Stable Angina
Primary: Change in Total Exercise Time (Seconds) — 24.3; 18.2; 33.9; 11.9 second
Phase 2 N=50 Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
Pancreatic Cancer
Primary: The Maximum Tolerated Radiation Dose — 55 Gray (Gy)
Phase 3 N=305 Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis
Psoriasis
Primary: Overall Disease Severity Success (ODS) — 100.0; 84.1 percentage of participants